Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Insulin pumps recalled due to malfunction risk—users warned to update software
The new Class I recall covers nearly 18,000 insulin pumps distributed throughout the United States. While this is not a product removal, users are being urged to update their devices immediately.
COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk
The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns.
Clinical trials paused due to heart patient’s hospitalization
Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury.

Insulin pumps recalled due to malfunction risk—users warned to update software

The new Class I recall covers nearly 18,000 insulin pumps distributed throughout the United States. While this is not a product removal, users are being urged to update their devices immediately.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.

Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly

Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.

Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk

The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns.

Clinical trials paused due to heart patient’s hospitalization

Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury.

New drug recall includes more than 140K bottles of popular statin

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

FDA approves oral semaglutide for reducing cardiovascular risks in adults with type 2 diabetes

Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes.

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM

No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?